tiprankstipranks
Advertisement
Advertisement

IMVT Stock Latest News

Immunovant price target raised to $47 from $35 at JPMorgan
The FlyImmunovant price target raised to $47 from $35 at JPMorgan
12d ago
IMVT
Immunovant price target raised to $62 from $44 at Guggenheim
PremiumThe Fly
Immunovant price target raised to $62 from $44 at Guggenheim
12d ago
IMVT
Immunovant price target raised to $30 from $23 at Truist
PremiumThe Fly
Immunovant price target raised to $30 from $23 at Truist
16d ago
IMVT
Immunovant’s Talent Crunch: How Human Capital Risks Could Derail IMVT-1402 Development Across Six Indications
PremiumCompany Announcements
Immunovant’s Talent Crunch: How Human Capital Risks Could Derail IMVT-1402 Development Across Six Indications
17d ago
IMVT
Immunovant price target raised to $43 from $32 at BofA
PremiumThe Fly
Immunovant price target raised to $43 from $32 at BofA
17d ago
IMVT
Immunovant price target raised to $40 from $35 at H.C. Wainwright
PremiumThe FlyImmunovant price target raised to $40 from $35 at H.C. Wainwright
17d ago
IMVT
Immunovant rises 33.6%
Premium
The Fly
Immunovant rises 33.6%
18d ago
IMVT
This Is Why Immunovant Stock (IMVT) Is Up Today
Premium
Market News
This Is Why Immunovant Stock (IMVT) Is Up Today
18d ago
IMVT
Immunovant rises 25.9%
PremiumThe Fly
Immunovant rises 25.9%
18d ago
IMVT
Immunovant reports Q4 EPS (73c), consensus (63)
PremiumThe Fly
Immunovant reports Q4 EPS (73c), consensus (63)
18d ago
IMVT
Insiders Dump Shares in Global-e, EyePoint, Immunovant, Nerdy, Argan
PremiumWeekend Updates
Insiders Dump Shares in Global-e, EyePoint, Immunovant, Nerdy, Argan
1M ago
AGX
EYPT
Immunovant price target raised to $32 from $29 at Goldman Sachs
PremiumThe Fly
Immunovant price target raised to $32 from $29 at Goldman Sachs
2M ago
IMVT
Elbit, Vor, Global-e, Sweetgreen, Immunovant: Insider Shake-Up
PremiumWeekend UpdatesElbit, Vor, Global-e, Sweetgreen, Immunovant: Insider Shake-Up
2M ago
SG
VOR
Strengthening the Buy Case for IMVT-1402: Targeted Phase 3 Graves’ Disease Strategy and Reproducible Efficacy Support Commercial Potential
Premium
Ratings
Strengthening the Buy Case for IMVT-1402: Targeted Phase 3 Graves’ Disease Strategy and Reproducible Efficacy Support Commercial Potential
2M ago
IMVT
Midday Fly By: Amazon said to eye Globalstar, Tesla deliveries miss consensus
Premium
The Fly
Midday Fly By: Amazon said to eye Globalstar, Tesla deliveries miss consensus
2M ago
F
BP
Buy Rating Maintained on Immunovant as IMVT-1402 Pipeline Overshadows Batoclimab Setback
PremiumRatings
Buy Rating Maintained on Immunovant as IMVT-1402 Pipeline Overshadows Batoclimab Setback
2M ago
IMVT
Immunovant price target lowered to $50 from $52 at Leerink
PremiumThe Fly
Immunovant price target lowered to $50 from $52 at Leerink
2M ago
IMVT
Morning Movers: Immunovant sinks after batoclimab trials miss goal
PremiumThe Fly
Morning Movers: Immunovant sinks after batoclimab trials miss goal
2M ago
BP
ALK
Video: Globalstar jumps after report of Amazon deal interest
PremiumThe Fly
Video: Globalstar jumps after report of Amazon deal interest
2M ago
CVX
DAL
Immunovant reports batoclimab clinical studies missed primary endpoint
PremiumThe FlyImmunovant reports batoclimab clinical studies missed primary endpoint
2M ago
IMVT
Bernstein initiates Immunovant with a Market Perform, $28 price target
Premium
The Fly
Bernstein initiates Immunovant with a Market Perform, $28 price target
3M ago
IMVT
Immunovant initiated with a Market Perform at Bernstein
Premium
The Fly
Immunovant initiated with a Market Perform at Bernstein
3M ago
IMVT

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >